The objective of this study was to determine the effects of in vitro embryo production on angiogenesis and morphometry of the bovine placenta during late gestation. Blastocysts produced in vivo were recovered from superovulated Holstein cows. Blastocysts produced in vitro were obtained after culture of in vitromatured and -fertilized Holstein oocytes. Single blastocysts from each production system were transferred into heifers. Fetuses and placentas were recovered on Day 222 of gestation (in vivo, n ‫؍‬ 12; in vitro, n ‫؍‬ 12). Cotyledonary and caruncular tissues were obtained for quantification of vascular endothelial growth factor (VEGF) and peroxisome proliferator-activated receptorgamma (PPAR␥) mRNA and protein. Tissue sections of placentomes were prepared for morphometric analysis. Fetuses and placentas were heavier from embryos produced in vitro than from embryos produced in vivo. More placentas from embryos produced in vitro had an excessive volume of placental fluid. There was no effect of treatment on the expression of mRNA for VEGF and PPAR␥ in either cotyledonary or caruncular tissues. The expression of VEGF protein in cotyledons and caruncles as well as the expression of PPAR␥ protein in cotyledons were not different between the in vitro and in vivo groups. However, caruncles from the in vitro group had increased expression of PPAR␥ protein. The total surface area of endometrium was greater for the in vitro group compared with controls. In contrast, the percentage placentome surface area was decreased in the in vitro group. Fetal villi and binucleate cell volume densities were decreased in placentomes from embryos produced in vitro. The proportional tissue volume of blood vessels in the maternal caruncles was increased in the in vitro group. Furthermore, the ratios of blood vessel volume density-to-placentome surface area were increased in the in vitro group. In conclusion, these findings are consistent with the concept that compensatory mechanisms exist in the vascular beds of placentas from bovine embryos produced in vitro.
INTRODUCTION
Proper development of the mammalian placenta is critical for determining nutrient availability to the developing fetus, regulation of gas exchange, and removal of waste products. Developmental problems of the fetus, the placenta, or both have been reported following transfer of in vitroproduced (IVP) embryos in cattle [1] [2] [3] [4] [5] and sheep [6, 7] . In cattle, these problems have included increased pregnancy loss, oversized or malformed fetuses and calves, increased hydrallantois, and other abnormalities of placental development [2, 4, 5] . Inadequate placental vascularization has also been observed in bovine [8] and ovine [9] placentas from embryos produced by somatic cell nuclear transfer. The influence of these in vitro embryo production systems on placental morphometry and angiogenesis is poorly understood.
Vascular development of the placenta is initiated by vasculogenesis and subsequently controlled by branching and nonbranching angiogenesis [10, 11] . Angiogenesis is regulated by growth factors, including vascular endothelial growth factor (VEGF; [12, 13] ), and potentially, peroxisome proliferator-activated receptor-gamma (PPAR␥), which has been shown to upregulate VEGF expression [14, 15] . In sheep, expression of VEGF mRNA was greater in both cotyledonary and intercotyledonary tissues compared with caruncular and intercaruncular tissues in early and late gestation [16] . Based on immunocytochemical localization, VEGF protein was greater in fetal placental tissues during early ovine pregnancy. However, during late pregnancy, VEGF protein was found primarily in the microvessels of maternal caruncular villi [16] . PPAR␥ has been associated with angiogenesis and tissue remodeling in the mammalian placenta [17, 18] and other organs [14, 15] . For example, in PPAR␥ knockout mice, epithelial differentiation of trophoblast tissue and placental vascular development were impaired, indicating that PPAR␥ is essential for these processes [17] . Expression of PPAR␥ mRNA has been demonstrated in the villi of choriodecidual placentas of humans [18] . In the human trophoblast, PPAR␥ has been shown to dimerize with retinoic acid receptor-␣ and regulate differentiation of extravillous cytotrophoblast [19] . Alterations in expression of angiogenic factors, such as VEGF and potentially PPAR␥, may play an important role in placental and fetal abnormalities associated with in vitro embryo production.
The overall objective of this study was to determine the effects of in vitro embryo production on the morphometry and angiogenesis of placentas during late gestation in cattle. Specifically, we compared placentas from embryos produced in vivo or in vitro for 1) gross and histological morphometry, 2) mRNA and protein expression for VEGF and PPAR␥ in cotyledonary and caruncular tissues, and 3) morphometry of blood vessels within the cotyledonary (fetal) and caruncular (maternal) components of placentomes.
MATERIALS AND METHODS

Reagents and Hormones
Tissue culture medium (M-199 with Earle salts) was purchased from Gibco BRL (Grand Island, NY). Equine pituitary LH (11.5 NIH LH-S1 units/mg) and porcine pituitary FSH (50 mg/vial; Armour FSH standard) preparations were obtained from Sigma Chemical Co. (St. Louis, MO). Fatty-acid-free BSA was purchased from Boehringer Mannheim (Indianapolis, IN). All other culture reagents and media were tissue-culture grade and were purchased from Sigma.
TRI-Reagent was purchased from Molecular Research Center, Inc. (Cincinnati, OH). DNase and random hexamers were purchased from Promega (Madison, WI). SuperScript II reverse transcriptase and dNTPs were purchased from Gibco BRL. PCR purification kits were purchased from Qiagen (Valencia, CA). QIAprep Miniprep system was purchased from Qiagen. Taq polymerase was purchased from Roche Molecular Biochemical (Indianapolis, IN). SYBR green dye was purchased from Molecular Probes, Inc. (Eugene, OR). All primers for PCR and real-time PCR were custom synthesized by either Sigma-Genosys (Woodlands, TX) or Qiagen Operon (Alameda, CA). For detection of VEGF protein by Western blot and immunocytochemistry, an anti-VEGF polyclonal rabbit antibody (sc-152) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). For detection of PPAR␥ protein by Western blot, an anti-PPAR␥ polyclonal rabbit antibody (107100) was purchased from Cayman Chemical (Ann Arbor, MI).
Production of Embryos
All procedures and protocols involving the use of animals were approved by the Institutional Animal Care and Use Committee at North Carolina State University. For in vivo embryo production, Holstein donor cows were synchronized using two i.m. injections of 25 mg prostaglandin F 2␣ (PGF 2␣ , lutalyse; Pharmacia and Upjohn Co., Kalamazoo, MI) 14 days apart. Donor cows were superovulated with 400 mg FSH (folltropin; Vetrapharm Canada, London, ON) administered in decreasing doses over a 4-day period beginning on Day 10, 11, 12, or 13 of the estrous cycle (Day 0 ϭ estrus). On the morning and evening of the third day of FSH treatment, estrus was induced using two i.m. injections of 25 mg of PGF 2␣ . Donors were artificially inseminated at 12 and 24 h after detection of first standing heat with thawed frozen semen from a proven Holstein bull. Embryos were collected by nonsurgical uterine flushing on Day 7 (Day 0 ϭ first detected estrus) [2] .
For in vitro embryo production, ovaries from Holstein cows were obtained at a local abattoir and held in saline with 0.75 g/ml penicillin for 4-6 h during transport to the laboratory. Cumulus-oocyte complexes (COCs) were aspirated, matured, and fertilized in vitro as previously described [2] . Briefly, COCs were aspirated from 2-to 7-mm follicles and washed five times in modified Tyrode medium (TL-HEPES). Groups of 20-30 COCs were matured for approximately 22 h in M-199 supplemented with 10% heat-inactivated estrus cow serum (ECS), 10 g/ml LH, 5 g/ml FSH, 1 g/ml estradiol, 200 M sodium pyruvate, and 50 g/ml gentamicin. All cultures were incubated at 5% CO 2 in air with 100% humidity. Following the maturation period, COCs were washed once and placed in fertilization medium that consisted of heparin-supplemented Tyrode albumin lactate pyruvate medium with 6 mg/ml fatty-acid-free BSA [20] . Thawed frozen semen from the same Holstein bull used for artificial insemination of donor cows was used for in vitro fertilization. Motile spermatozoa were collected using the swim-up procedure [20] and a final concentration of 1 ϫ 10 6 spermatozoa per ml was used for fertilization in 0.75 ml of fertilization medium. Spermatozoa and COCs were coincubated for 18-20 h. Following incubation, presumptive zygotes were washed six times with TL-HEPES and placed in 1 ml M-199 supplemented with 10% ECS and 50 g/ml gentamicin. Embryos were incubated for a 168-h culture period and culture medium was changed at 48-h intervals.
Transfer of Embryos
Angus heifers were given two injections of 25 mg of PGF 2␣ by i.m. administration 10-12 days apart to synchronize estrus. Grade 1 blastocysts [21] from in vivo or in vitro production systems were transferred in TL-HEPES medium singly into the uterine horn ipsilateral to the ovary bearing the corpus luteum of recipient heifers on Day 7 of the estrous cycle.
Recovery of Fetuses and Placental Tissue
At Day 222 of gestation (215 days after transfer), a total of 24 pregnant recipients (n ϭ 12 and 12 for in vivo and in vitro, respectively) were killed. Fetuses and their placentas were removed from the reproductive tracts and physical measurements were taken, including fetal weight, wet placental weight, number of placentomes, and placental fluid (amniotic plus chorioallantoic fluid) volume. Samples of cotyledonary and caruncular tissues were obtained by careful manual separation of these tissues.
Tissues were immediately snap frozen in liquid nitrogen and stored at Ϫ80ЊC for whole-cell RNA (wcRNA) and protein extraction. Center segments cut from whole placentomes of individual placentas were stored in 10% neutral buffered formalin for histology and immunocytochemistry. After removal of the placenta, the entire uterus was opened completely and laid flat with the endometrial surface exposed. A top-view, digital photograph of the uterine endometrial surface was taken for morphometric analysis.
Processing of Tissue for RNA and Protein
For wcRNA extraction, frozen cotyledonary and caruncular tissues were removed from storage, weighed, placed in a frozen mortar, covered with liquid nitrogen, and crushed to a fine powder. The fine powder was resuspended in TRI-Reagent (1 ml/100 mg tissue) and samples were homogenized (Brinkmann Homogenizer PT 10/35; Westbury, NY). Wholecell RNA was extracted according to the manufacturer's protocol and dissolved in diethyl pyrocarbonate-treated water. The concentration of the wcRNA was determined by absorbance at 260 nm. The quality and integrity of the wcRNA was assessed based on the ratio of absorbance at 260 and 280 nm and visualization of 28S and 18S rRNA bands in ethidium bromide-stained agarose gels (data not shown). Aliquots of approximately 30 g of wcRNA were stored at Ϫ80ЊC until used for cDNA synthesis.
For protein extraction, frozen cotyledonary and caruncular tissue samples were removed from storage, weighed, placed in a frozen mortar, covered with liquid nitrogen, and crushed to a fine powder. The powder was resuspended as previously described [22] in a cold buffer (13.3 l buffer/ mg of tissue) consisting of 1% (v/v) Triton X-100, 2 mM EDTA, 2 mM EGTA, aprotinin (20 g/ml), leupeptin (20 g/ml), 1 mM PMSF, and 20 mM HEPES. Samples were stored on ice, homogenized (Brinkmann Homogenizer), and transferred to 1.5-ml tubes. Samples were then centrifuged at ϳ10 000 ϫ g for 10 min at 4ЊC. The supernatant was collected and stored at Ϫ20ЊC. Total protein was quantified using bicinchoninic acid protein assay (Pierce, Rockford, IL) according to the manufacturer's suggested protocol.
Reverse Transcription and Verification of PCR Products
Individual aliquots of wcRNA were thawed on ice and 2 g of each sample was treated with DNase (1.5 U) for 20 min at 37ЊC. Reactions were stopped by the addition of 2 l of 20 mM EDTA. Following DNase inactivation, wcRNA was reverse transcribed using random hexamers and SuperScript II reverse transcriptase under conditions recommended by the manufacturer. Following cDNA synthesis, samples were purified using the Qiagen PCR purification kit as recommended by the manufacturer and stored at 4ЊC.
Primer sequences for VEGF-1 were designed using Oligo 4.0.2 Primer Analysis software (Plymouth, MA) and Gene Amplify 1.2 software (Madison, WI) and based on sequences reported by Leung et al. [23] (Table 1) . Forward and reverse primer pairs for glyceraldehdye-3-phosphate dehydrogenase (GAPDH) and PPAR␥ were obtained from Leutenegger et al. [24] and Sundvold et al. [25] , respectively (Table 1) . A VEGF-2 forward and reverse primer pair, specifically designed to detect all five VEGF isoforms [26] , was used (Table 1 ). For verification of PCR reaction, each reaction consisted of 100 ng equivalents of cotyledonary cDNA, 1.6 M of the appropriate forward and reverse primers, 16 M dNTPs, 2 l of 10ϫ PCR buffer (Roche), and 2.5 U of Taq polymerase in a 20-l reaction. A negative control lacking cDNA was included for each PCR assay. All PCR reactions were run in 96-well PCR plates and briefly spun before placing into an iCycler thermocycler (Bio-Rad, Richmond, CA). Each PCR program consisted of a 90-sec hot start at 95ЊC, followed by 35 cycles of 30-sec denaturation at 94ЊC, 30-sec annealing at 60ЊC, and primer extension for 30 sec at 72ЊC. Following the cycles, an additional primer extension for 5 min at 72ЊC was used. The primer sequences used for PCR validation with their expected product lengths and specific isoforms are shown in Table 1 . The PCR products from VEGF-1, VEGF-2, GAPDH, and PPAR␥ primer pairs were verified by sequence analysis.
Real-Time Quantitative PCR Analysis
Verified GAPDH, VEGF-1, and PPAR␥ primers were used for quantification of GAPDH, VEGF, and PPAR␥ mRNA levels by real-time reverse transcription-PCR using a SYBR Green I detection system. Quantification was performed using a two-tube PCR system. Whole-cell RNA was subjected to reverse transcription in a separate tube and cDNA was transferred to 96-well PCR plates for real-time PCR using the iCycler (Bio-Rad). SYBR Green I, a high-affinity double-stranded DNA binding [24] . d Primer from [25] . e Primer from [26] .
dye, was used to monitor DNA amplification [27] . For analysis of cotyledonary tissue, each PCR reaction consisted of 100 ng equivalents of cDNA, 1.6 M of the appropriate forward and reverse primers, 16 M dNTPs, 2 l of 10ϫ PCR buffer, 2 l of 2ϫ SYBR Green I dye, 1 l of 200 nM Fluorescein dye (Bio-Rad), and 2.5 U of Taq polymerase in a 20-l reaction. For analysis of caruncular tissue, PCR methods were the same as those described for cotyledonary tissue, except that only 50 ng equivalents of cDNA was used. Melt-curve analysis and gel electrophoresis were used to confirm product length after amplifications were complete (data not included). In real-time PCR, the threshold (C T ) is evaluated during the log-linear phase of the PCR amplification and is an exponential term, not a linear term [28] . Therefore, C T values were converted to linear terms using the formula for calculation of mRNA levels for VEGF ϪC T 2 and PPAR␥ [29] . Expression of mRNA for VEGF and PPAR␥ in individual samples was analyzed as a ratio of linearized C T values of mRNA for VEGF or PPAR␥ to the linearized C T values of GAPDH.
Expression of mRNA in cotyledons and caruncles were analyzed separately. For each tissue type, two assays were used (in vivo, n ϭ 6, and in vitro, n ϭ 6 within each assay for each tissue). Each assay also contained reference samples of cotyledonary or caruncular tissue from a random control bovine placenta at approximately Day 220 of gestation (fetal crown-rump length ϭ 75.0 cm). The random reference samples were used to determine inter-and intraassay coefficients of variation (CVs) for the linearized C T values. The inter-and intraassay CVs for VEGF assays of cotyledons were 10.4% and 21.2%, respectively. The inter-and intraassay CVs for PPAR␥ assays of cotyledons were 7.4% and 17.1%, respectively. The inter-and intraassay CVs for VEGF assays in caruncles were 24.3% and 4.9%, respectively. The intraassay CV for PPAR␥ assays in caruncles was 12.1%. Because the interassay CVs for the two PPAR␥ assays for caruncles was greater then 25%, values from the second PPAR␥ assay were normalized to the first PPAR␥ assay.
Western Blot
Expression of VEGF and PPAR␥ was evaluated using a modified Western blot protocol [22] . Briefly, 20 mg of total protein from cotyledonary or caruncular tissues was separated on 12% (w/v) SDS-PAGE gels under nonreducing conditions. Following electrophoresis, the polyacrylamide gels were transferred to nitrocellulose membranes (Bio-Rad) using a semidry transfer system (Bio-Rad). VEGF and PPAR␥ antibody binding was detected using the BM Chemiluminescence Western blotting kit (mouse/ rabbit; Roche Applied Science). Nonspecific binding sites were blocked with 1% blocking solution. Blots were incubated overnight at 4ЊC with a 1:500 dilution of VEGF polyclonal antibody or 1:750 dilution of PPAR␥ polyclonal antibody. Specificity of the VEGF and PPAR␥ antibodies was verified using blocking peptides obtained from Santa Cruz Biotechnology, Inc., and Cayman Chemical, respectively. Blocking peptides were incubated with their respective primary antibody (5:1 and 3:1 for VEGF and PPAR␥, respectively) for 1 h at room temperature (RT) immediately before overnight primary antibody incubations with protein-bound membranes. Following primary antibody incubation, blots were washed with 0.5% blocking solution twice for 10 min each and then twice with Tris-buffered saline-Tween20 (TBST) buffer for 10 min. Following washing, the blots were incubated for 30 min at RT with a 1:500 dilution of horseradish peroxidase-labeled anti-mouse IgG/anti-rabbit IgG (40 mU/ml). Following incubation with the secondary antibody, the blots were washed four times for 10 min in TBST buffer. Blots were incubated with a prewarmed (RT) detection solution for 1 min, exposed to Kodak X-OMAT-AR film (Eastman Kodak, Rochester, NY), and binding was quantified using computerassisted video image analysis (Optimas Visual Imaging System 6.1; Optimas Corporation, Bothell, WA).
Morphometric Analysis
Computer-assisted image analyses (Optimas Visual Imaging System 6.1) of digital photographs of the entire endometrial surface of the uterus were used to quantify total uterine and caruncular surface areas. Caruncular surface area was used to assess the proportion of the total uterine endometrial surface area occupied by placentomes; hereafter referred to as placentome surface area.
Samples of intact placentomes were embedded in paraffin and 5-m sections of placentome tissues were prepared. Sections were deparaffinized, dehydrated, and stained with hematoxylin-eosin. Stereologic end points, including the volume densities of fetal villi, caruncular endometrium, binucleate cells, and fetal and maternal pyknotic cells, were evaluated by point-count methods [30, 31] using computer-assisted image analysis. For analysis of fetal villi, maternal endometrium, and binucleate cells, 10 fields of view representing a total of 8.12 ϫ 10 6 m 2 of each placentome section was examined using a 100-point grid system [31] . For analysis of fetal and maternal pyknotic cells, 10 fields of view representing a total of 6.01 ϫ 10 4 m 2 from each placentome section was examined using a 256-point grid system [31] .
Immunocytochemical localization of VEGF protein was used to identify vascular beds for morphometric analysis. Following deparaffinization, tissue sections were incubated for 5 min in Target Unmasking Fluid (BD Pharmingen, San Jose, CA) at 90ЊC to increase antigen availability within the tissue. Endogenous peroxidase activity was blocked using 0.5% hydrogen peroxide and nonspecific binding was blocked using normal goat serum (1:67 in PBS). Immunoreactivity for VEGF was detected using a 1:50 dilution of the VEGF polyclonal antibody. Placentome sections were incubated with primary antibody for 1 h at RT. Specificity of the VEGF antibody was verified using blocking peptide obtained from Santa Cruz Biotechnology, Inc. Blocking peptide was incubated with primary antibody (5:1) for 1 h at RT before primary antibody incubation with placentome sections. Biotinylated goat anti-rabbit IgG (1:200 in PBS) was used as a secondary antibody. Following incubation with the secondary antibody, placentome sections were incubated with avidin and biotinylated horseradish peroxidase and then visualized with diaminobenzidine tetrahydrochloride containing nickel (Vector Laboratories, Burlingame, CA).
For analysis of maternal and fetal blood vessels, 20 fields of view representing a total of 4.8 ϫ 10 5 m 2 of tissue was examined from each placentome section. Point-count methodology with a 256-point grid system [31] was used to determine the volume densities of maternal and fetal blood vessels. For determination of total blood vessels, volume densities of maternal and fetal blood vessels were added. To determine the relative amount of maternal, fetal, and total blood vessels within the proportion of uterine endometrial surface area occupied by placentomes for each animal, 
Statistical Analysis
Proportional data for placental fluid volumes were analyzed using the chi-square test [32, 33] . All other data were analyzed using general linear model procedures [32, 33] and results are reported as least-squares means Ϯ SEM. Means were considered statistically different at P Յ 0.05 and tendencies between P ϭ 0.06 and P ϭ 0.10.
The model for the analysis of fetal body weight, placental weight, and placental efficiency (fetal body weight/placental weight, [34] ) included only the main effect of treatment because the effects of sex and the interaction of treatment by sex were nonsignificant and these effects did not increase the R 2 value. For the analysis of placental fluid volume, number of placentomes, uterine and placentome surface areas, and histological morphometry of placentas, the model included the main effects of treatment, sex of fetus, interaction of treatment by sex of fetus, and the covariate placental weight. The model for the analysis of mRNA for VEGF and PPAR␥ as well as protein for VEGF and PPAR␥ included the main effects of treatment, sex of fetus, real-time PCR assay or protein gel, all two-way interactions between main effects, and the covariate placental weight.
RESULTS
Morphometry of Fetuses and Placentas
Fetuses from embryos produced in vitro were heavier (P ϭ 0.03) than fetuses from embryos produced in vivo (Table  2 ). In addition, placentas from the in vitro group tended to be heavier (P ϭ 0.06) than those in the in vivo group. Interestingly, placental efficiency (fetal weight/placental weight) was similar for the two treatment groups. Also, the number of placentomes was similar for the two treatment groups. No statistical difference between treatment groups was observed in placental fluid volume. However, the range of placental fluid volumes was more extreme in placentas in the in vitro group (29.5 L) compared with those in the in vivo group (7.5 L). In addition, the proportion of placentas with greater than 8.0 L (1 standard deviation above the unadjusted mean value of 6.0 L for the in vivo control group) of placental fluid volume was greater (P ϭ 0.04) in placentas from the in vitro group (7 of 12; 58%) compared with placentas from the in vivo group (2 of 12; 17%).
Morphometry of placentas from embryos produced either in vivo or in vitro is summarized in Table 2 . Total uterine surface area was greater (P ϭ 0.008) for pregnancies resulting from IVP embryos compared with those from in vivo-produced embryos. However, the percent placentome surface area was less (P ϭ 0.003) for the in vitro group compared with the in vivo group. Figure 1 shows a section of placentome demonstrating both maternal and fetal components. Based on morphometric analysis of placentomes, volume density of fetal villi was less (P ϭ 0.01) in placentas from embryos produced in vitro compared with those produced in vivo. Conversely, volume density of caruncular endometrium was greater (P ϭ 0.01) in placentas of the in vitro group compared with those of the in vivo group. The volume density of fetal binucleate cells tended (P ϭ 0.09) to be reduced in placentas of the in vitro group. There was no effect of treatment on the volume density of pyknotic cells within the fetal villi or the maternal endometrium. Figure 2 shows the amplification products from the VEGF-2 primer pair from cotyledonary and caruncular tissue of placentas from embryos produced in vivo or in vitro. Three bands were visualized at expected lengths corresponding to the VEGF 120 , VEGF 164 , and VEGF 188 isoforms [26] for cotyledonary and caruncular tissue from placentas of embryos produced in vitro and in vivo. In cotyledonary tissue, VEGF 164 appeared to be the predominant isoform expressed. In contrast, in caruncular tissue, VEGF 120 appeared to be expressed to a greater extent than VEGF 164 .
Expression of VEGF and PPAR␥ mRNA
The expression of mRNA for VEGF and PPAR␥ in cotyledonary and caruncular tissues is summarized in Table 3 . Based on real-time PCR, the expression of VEGF mRNA was not different in cotyledonary tissue from embryos produced in vitro compared with embryos produced in vivo. Similarly, the expression of VEGF mRNA was not different in caruncular tissue in the in vitro group compared with the in vivo group. The expression of PPAR␥ mRNA in cotyledonary tissue was not different between the in vitro group and the in vivo group. The expression of PPAR␥ mRNA in caruncular tissues was also not different in caruncular tissue from embryos produced in vitro compared with embryos produced in vivo.
VEGF and PPAR␥ Protein
Binding of VEGF and PPAR␥ antibodies to both cotyledonary and caruncular tissue proteins resulted in bands at approximately 20 kDa and 50 kDa, respectively (data not shown). Preincubation of each antibody with their respective blocking peptide eliminated the antibody signal (data not shown). The expression of protein for VEGF and PPAR␥ in cotyledonary and caruncular tissues is summarized in Table 3 . The expression of VEGF protein was not different in cotyledonary tissue from the in vitro compared with the in vivo group. Also, the expression of VEGF protein in caruncular tissue was not different between the in vitro and in vivo groups. The expression of PPAR␥ protein was not different in cotyledonary tissue from placentas of embryos produced in vitro compared with embryos produced in vivo. However, the expression of PPAR␥ protein in caruncular tissues was increased (P ϭ 0.01) for the in vitro group compared with the in vivo group.
Placental Vascular Morphometry
Blood vessels within the caruncular endometrium and fetal villi were visualized using immunohistochemical staining for VEGF protein (Fig. 3) . The volume density of fetal blood vessels did not differ in placentomes from embryos produced in vitro (5.4% Ϯ 0.3%) compared with embryos produced in vivo (5.4% Ϯ 0.3%; Fig. 4) . The volume density of total blood vessels was not different in placentomes from embryos produced in vitro (11.2% Ϯ 0.4%) compared with embryos produced in vivo (10.3% Ϯ 0.4%; Fig. 4 ). In contrast, the volume density of maternal blood vessels was significantly (P ϭ 0.02) greater in placentomes from the in vitro group (5.9% Ϯ 0.2%) compared with the in vivo group (4.9% Ϯ 0.2%; Fig. 4 ). The ratio of fetal blood vessel density-to-placentome surface area was increased (P ϭ 0.02) in the in vitro group (0.10 Ϯ 0.01) compared with the in vivo group (0.08 Ϯ 0.01; Fig. 5) . Similarly, the ratio of maternal blood vessel density-toplacentome surface area was increased (P ϭ 0.001) in the in vitro group (0.11 Ϯ 0.01) compared with the in vivo FIG. 5 . Ratios of fetal, maternal, and total blood vessels-to-placentome surface area (least-squares means Ϯ SEM) in bovine placentas following transfer of embryos produced in vivo (n ϭ 12) or in vitro (n ϭ 12). *, P ϭ 0.02; **, P ϭ 0.001. group (0.07 Ϯ 0.01; Fig. 5) . Furthermore, the ratio of total blood vessel density-to-placentome surface area was increased (P ϭ 0.001) in the in vitro group (0.20 Ϯ 0.01) compared with the in vivo group (0.15 Ϯ 0.01; Fig. 5 ).
DISCUSSION
Consistent with previous reports [1-7, 35, 36] , fetuses and placentas resulting from embryos produced in vitro in the present study were heavier than in vivo controls. Pregnancies resulting from IVP embryos compared with in vivo controls had a more extreme range of placental fluid volume, with an increased proportion of placentas displaying elevation in placental fluid volume (i.e., hydrallantois). These findings are consistent with the observations of Hasler et al. [1] , who observed higher incidence of hydrallantois from pregnancies resulting from IVP embryos compared with normal pregnancies. Compared with placentas from the in vivo group, placentas from the in vitro group had decreased feto-maternal contact area as measured by placentome surface area and fetal villous volume density. In contrast, placentas from the in vitro group had an increased proportional volume of blood vessels in the maternal caruncles compared with controls. In addition, the ratios of volume densities for fetal, maternal, and total blood vessels-to-placentome surface area were increased in the in vitro group. Taken together, these observations suggest that placentas resulting from embryos produced in vitro may have developed compensation mechanisms in their vascular beds to ameliorate the decreased area available for fetomaternal contact.
The chorioallantoic placenta provides the major source of exchange between the developing fetus and uterine endometrium [37] . Formation of the chorioallantoic placenta results from the fusion of the nonvascular chorion with the vascularized allantoic membrane [37] . A major feature of the chorioallantoic placenta, compared with other types of mammalian placentas, is an increased surface area at the feto-maternal junction. In the cow, this increase in placental surface area occurs by the formation of chorionic villi within the cotyledonary plaques that consist of vascular mesenchymal cones surrounded by cuboidal, mononucleate, and binucleate trophoblastic cells. These cones, or villi, interdigitate with vascular foldings of the uterine caruncular endometrium [38] . Fetal cotyledons attach to maternal caruncles to form approximately 70-120 placentomes that serve as the functional unit for feto-maternal exchange [39] .
By Day 170 of gestation, the bovine placenta is fully developed [40] . However, placentomes continue to enlarge, resulting in the characteristic mushroom-like shape [41] .
Results of the current study suggest that, during late gestation, placentas from embryos produced in vitro may be compromised relative to control placentas with respect to demands for adequate feto-maternal exchange. The observations that pregnancies from IVP embryos have larger, heavier placentas and higher incidence of hydrallantois that display a decreased placentome surface area and a decreased volume density of fetal villi support this hypothesis. These findings are in contrast with those of Bertolini et al. [5] , who observed that enlarged cotyledons were associated with greater cotyledonary surface area in term placentas from bovine embryos produced in vitro compared with those produced in vivo [5] . The discrepancy in results between this study and Bertolini et al. [5] may be attributed to differences in the time of gestation examined (7 mo versus term). Our observations suggest that development is limited in placentomes in the in vitro group. Abnormal development of the placentome has also been observed in bovine placentas from nuclear transfer embryos during late gestation [42, 43] .
Placentas in the in vitro group also tended to have decreased volume density of fetal binucleate cells. This observation is consistent with the suggestion that placental development is altered in placentas from embryos produced in vitro. Fetal binucleate cells produce a variety of hormones, such as placental lactogen and pregnancy-associated glycoproteins, which play an essential role in maintenance of normal pregnancy [44] .
In the normal placentome of the cow, extensive development of the vasculature occurs during late gestation [34] . In the placenta, increased blood flow results in favorable conditions that enhance exchange of materials within capillary beds [41] . Blood flow within the placenta increases by angiogenesis [16] , a process that is predominantly regulated by VEGF, fibroblast growth factor (FGF), and angiopoietins [10, 45] . In the present study, we have shown that mRNA for VEGF was expressed in both cotyledonary and caruncular tissues. However, there was no effect of treatment on the levels of mRNA expression for VEGF in either cotyledonary or caruncular tissues. In addition, no differences between treatment groups were found for VEGF protein in either cotyledonary or caruncular tissues. These findings imply that, at Day 222 of gestation, bovine placentas resulting from embryos produced in vitro do not have alterations in placental angiogenesis, at least based on assessment of VEGF mRNA and protein. However, it remains possible that VEGF mRNA and protein may be altered at other stages of gestation in bovine placentas from embryos produced in vitro. Alternatively, other angiogenic factors, such as FGF or angiopoietins, may be altered in bovine placentas resulting from in vitro production of embryos.
The predominant VEGF isoform detected in late gestation bovine cotyledonary tissue in the present study was VEGF 164 . This finding is consistent with the report by Cheung and Brace [26] , who found that VEGF 164 was the predominant isoform in ovine cotyledons. Interestingly, the most abundant VEGF isoform found in bovine caruncles in the present study was VEGF 120 . Expression of the VEGF 144 or VEGF 205 isoforms was not detected in either cotyledons or caruncles. Together, these findings suggest that differences may exist among ruminant species in the patterns of expression of VEGF isoforms in cotyledonary and caruncular tissues.
PPAR␥, a transcription factor, has been shown to upregulate VEGF expression in macrophages [14] and vascular smooth muscle [15] . PPAR␥ has also been shown to play a critical role in vascular development of placentas in mice [17] . Furthermore, PPAR␥ plays an important role in regulating the differentiation of extravillous cytotrophoblast in human placentas [19] . Because PPAR␥ plays a role in development and organization of the placenta, we wanted to determine if PPAR␥ was altered in bovine placentas from embryos produced in vitro or in vivo. In the present study, PPAR␥ mRNA and protein was expressed in both cotyledonary and caruncular tissues from late gestation bovine placentas. Expression of PPAR␥ mRNA was not different in either cotyledonary or caruncular tissues between the in vitro and in vivo groups. In addition, no difference between the in vivo and in vitro groups was found in cotyledonary levels of protein for PPAR␥. In contrast, the caruncular levels of PPAR␥ protein were increased for the in vitro group compared with the in vivo group. The discrepancy between mRNA and protein for PPAR␥ in the in vitro group may be explained by an increased turnover from mRNA to protein within the caruncles. The increase of PPAR␥ protein observed in caruncular tissues of the vitro group suggests that these placentas may have enhanced vascular development compared with placentas from the in vivo group.
Fetal vascular volume densities in placentomes were similar for the in vivo and in vitro groups. Conversely, maternal vascular volume density was increased in placentomes in the in vitro group compared with the in vivo group. Interestingly, the ratios of volume densities of fetal, maternal, and total blood vessels-to-placentome surface area were all increased in placentas from embryos produced in vitro compared with in vivo controls. These findings suggest that vascular development was enhanced in the placentomes resulting from embryos produced in vitro. Enhanced vascular development observed in these placentomes was not associated with changes in levels of mRNA or protein expression for VEGF. However, the levels of PPAR␥ protein in the caruncular tissue of placentas from the in vitro group were increased, suggesting that vascular development of these placentas may be modulated by PPAR␥ or other angiogenic factors such as FGF or angiopoietins [45] . Alternatively, mRNA and protein for VEGF may be altered at an earlier stage of gestation, thus, driving enhanced development of the placental vasculature observed in placentas from embryos produced in vitro.
In conclusion, compared with placentas from embryos produced in vivo, placentas from embryos produced in vitro appear to compensate for decreased feto-maternal contact with an increased proportion of blood vessels within the cotyledonary and caruncular tissues of the placentome. These findings are consistent with the concept that compensatory mechanisms are present during late gestation in the vascular beds of placentas from bovine embryos produced in vitro.
